It is proposed to carry out the study in three medical or surgical intensive care units (ICU) in the CHRU, Lille, and the CHU, Besançon. In all patients admitted to these ICU (see Figure 2), a corrected index of colonisation (CIC) will be determined and blood samples will be taken for genotyping of the lectins MBL, Dectin-1 and Galectin-3 and for serology. Over the duration of hospitalisation (on average 28 days) and weekly, fungal colonisation will be assessed in all patients (according to the CIC), and antibodies to yeast glycans will be determined by a simultaneous multiparametric analysis involving several families of natural or synthetic antigens, and the detection of circulating antigens (mannan and β-1,3 glucan).
Determination of the CIC: The CIC will be determined on admission and then once a week during hospitalisation. This will be carried out on a fixed day for all patients; we will avoid determining the CIC any closer than 2 days apart. It is not planned in this study to modify the therapeutic strategy of the ICU services. The strains isolated will be stored in glycerol solution at -80°C. The specimens for genetic and serological analysis will be stored centrally in a local mycology laboratory. Genotyping of lectin genes and TLRs: Two tubes containing 6 ml of blood in EDTA will be taken from each patient for extraction of DNA Serological study, detection of antibodies to yeast glycans: 10 ml of whole blood will be taken from each patient on the day of inclusion and over the duration of hospitalisation (maximum total quantity of 40 ml). This will be done on a fixed day for all patients; we will avoid sampling any closer than 2 days apart. Functional tests on peripheral blood mononuclear cells (PBMCs) Taking into account the fact that the results of genotyping will not be available in real time and the need to work with freshly collected cells, a group size of 50 patients in group 2 (negative CIC over the duration of hospitalisation) and 50 patients in group 3 (negative CIC at admission but positive at hospital discharge) will be analysed. Stimulation tests will be carried out in the presence of whole yeasts or yeast extracts on sub-populations of cells isolated from 20 ml of peripheral blood in EDTA.
Study Type
OBSERVATIONAL
Enrollment
2,200
CHRU de Lille
Lille, Nord, France
Centre hospitalier
Arras, France
Centre hosptialier
Boulogne-sur-Mer, France
CH Schaffner
Lens, France
Hôpital Saint-Philibert
Lomme, France
CH Victor Provo
Roubaix, France
Frequency of polymorphisms
the frequency is measured for the association between the presence of a polymorphism and colonization by Candida sp. frequency of polymorphisms at least one lectin gene or TLRs between some colonized patients (G5) and the non-colonized patients (G2).
Time frame: From date of inclusion until the last day hospital stay (at once a week)
Genotyping of lectin genes and toll-like-receptors (TLRs)
The analysis relates to genetic factors already described for lectins and will also include variants of genes involved in innate immunity host-microorganism interactions such as TLRs
Time frame: From date of inclusion until the last day hospital stay (at once a week)
Colonization index
This index is calculated for each patient at the entrance of the service and then once a week until discharge (at least two weeks after admission). This index is the ratio between the number of body sites colonized heavily on the number of body sites explored when at least one colony of Candida spp. was observed. The determination of Candida colonization index requires the implementation of several samples from different body sites. The sampled anatomical sites concern 1. mouth (oropharyngeal swab) 2. stomach (gastric aspiration) 3. trachea (tracheal suctioning) 4. urine 5. rectum (rectal swab or stool).
Time frame: at admission and weekly for at least two weeks after.
Functional tests on peripheral blood mononuclear cells (PBMC)
Functional tests on peripheral blood mononuclear cells (PBMC) obtained from mutated patients for given Innate-immunity genes will be carried out through stimulation tests in the presence of whole yeast or derived-molecules on isolated cell subpopulations.
Time frame: at admission and weekly for at least two weeks after.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.